Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT-I10A in advanced solid tumors or lymphoma
NCT03821363Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of finotonlimab in solid tumor (advanced stage) and lymphoma (3 arms), sponsored by Sinocelltech Group Limited. Primary endpoint: Safety and Tolerability at 24 months. Status: unknown.
02
Drugs
finotonlimab
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT03821363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821363.